Clinical Trials
83 trialsSTARTRK-2
Hoffmann-La Roche
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
PSI-Immune
University of Pittsburgh
MK-3475A-F11
Merck Sharp & Dohme LLC
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
Tamarack
MacroGenics
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Incyte Corporation
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
PAVO
Tempus AI
AGADIR
Institut Bergonié
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
MITRIC
Oslo University Hospital
INTROSPECTION
Maria Sklodowska-Curie National Research Institute of Oncology
ACROPOLI
SOLTI Breast Cancer Research Group
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
IL2HD
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
PRETZCEL
ImaginAb, Inc.
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Henan Cancer Hospital
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
ICONIC
CNAO National Center of Oncological Hadrontherapy
iPREDICT
ImaginAb, Inc.
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
CHEERS
University Hospital, Ghent
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Convalife (Shanghai) Co., Ltd.
ALpha-T
Hoffmann-La Roche
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Qilu Pharmaceutical Co., Ltd.
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Bristol-Myers Squibb